Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Zenopa are a well organised company that see the hole picture ahead of them with a defined timescale they work to.
Barry , 2013

Orion reports 12 percent rise in half-year sales

3 August 2011 00:00 in Pharmaceutical Company Financials

Orion has announced that its sales for the first half of 2011 totalled 471 million euros (410.4 million pounds), representing an increase of 12 percent on the corresponding period last year.

The Finnish pharmaceutical company posted an operating profit of 158 million euros for the six-month period, up from 131 million euros in 2010.

Its operating profit for the second quarter, 65.1 million euros, was roughly in line with the average forecast of 65.7 million euros taken from a Reuters poll of analysts.

Timo Lappalainen, president and chief executive of Orion, said the firm had delivered "solid growth" in a challenging environment.

He added: "Sales of our Parkinson's drugs continued to rise, mainly because deliveries to Novartis increased. Sales from our other product ranges grew throughout the first half of the year."

Mr Lappalainen said the company has strengthened its position in Finland while maintaining its growth in the Scandinavian and eastern European markets.

Orion upgraded its full-year outlook for 2011 in April due to encouraging first-quarter sales figures.ADNFCR-8000103-ID-800674916-ADNFCR

Other news stories from 03/08/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd